DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Micardis® (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis collected during the clinical studies.

Clinical Details

Official title: Safety, Tolerability and Efficacy of Micardis (Telmisartan) in Patients With Essential Hypertension

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Indicence of ulcera

Incidence of gastrointestinal (GI) bleedings

Secondary outcome:

Incidence of adverse events (GI-complaints inclusive)

Change from baseline in office blood pressure

Response rate

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients of both sexes with essential hypertension and a minimum age of 18 years

Exclusion Criteria: (Not applicable)

Locations and Contacts

Additional Information

Starting date: January 1999
Last updated: July 7, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017